Perjeta (Pertuzumab) vs Nerlynx (neratinib)
Perjeta (Pertuzumab) vs Nerlynx (neratinib)
Perjeta (pertuzumab) and Nerlynx (neratinib) are both targeted therapies used to treat HER2-positive breast cancer, but they work in different ways and are used at different stages of treatment. Perjeta is often used in combination with Herceptin (trastuzumab) and chemotherapy as part of a neoadjuvant (before surgery) or adjuvant (after surgery) treatment for early-stage breast cancer, or for metastatic cases. In contrast, Nerlynx is used as an extended adjuvant treatment specifically after Herceptin-based therapy to further reduce the risk of cancer recurrence. The choice between these medications should be made in consultation with an oncologist, based on the specific characteristics of the cancer, the patient's medical history, and the treatment regimen being followed.
Difference between Perjeta and Nerlynx
Metric | Perjeta (Pertuzumab) | Nerlynx (neratinib) |
---|---|---|
Generic name | Pertuzumab | Neratinib |
Indications | HER2-positive breast cancer | Extended adjuvant treatment of HER2-positive early-stage breast cancer |
Mechanism of action | HER2 dimerization inhibitor | Tyrosine kinase inhibitor |
Brand names | Perjeta | Nerlynx |
Administrative route | IV infusion | Oral |
Side effects | Diarrhea, hair loss, nausea, neutropenia, fatigue | Diarrhea, nausea, abdominal pain, fatigue, rash |
Contraindications | Hypersensitivity to pertuzumab or excipients | Liver impairment, severe renal impairment, uncontrolled hypertension |
Drug class | Monoclonal antibody | Tyrosine kinase inhibitor |
Manufacturer | Genentech (Roche) | Puma Biotechnology |
Efficacy
Efficacy of Perjeta (Pertuzumab) in Breast Cancer Treatment
Perjeta (Pertuzumab) is a monoclonal antibody that targets the HER2 receptor, a protein that can promote the growth of cancer cells. In the treatment of breast cancer, Pertuzumab is specifically used for HER2-positive breast cancers, which are known to be more aggressive than HER2-negative cancers. The efficacy of Pertuzumab in breast cancer treatment has been demonstrated in several clinical trials. When used in combination with trastuzumab and chemotherapy, Pertuzumab has been shown to significantly improve progression-free survival in patients with metastatic HER2-positive breast cancer. Additionally, this combination has been found to increase the rate of pathological complete response in the neoadjuvant setting, which can be an indicator of improved long-term outcomes.
In the adjuvant setting, for early-stage HER2-positive breast cancer, Pertuzumab has been studied in combination with trastuzumab and chemotherapy. The APHINITY trial, a pivotal study in this context, showed that adding Pertuzumab to standard therapy reduced the risk of recurrence or death compared to trastuzumab and chemotherapy alone. However, the benefit was modest, and the use of Pertuzumab in the adjuvant setting is considered based on the individual patient's risk of recurrence and overall health status.
Efficacy of Nerlynx (neratinib) in Breast Cancer Treatment
Nerlynx (neratinib) is an oral tyrosine kinase inhibitor that also targets the HER2 protein and is used in the treatment of HER2-positive breast cancer. The efficacy of neratinib was notably established in the ExteNET trial, which was a large international, randomized, double-blind, placebo-controlled Phase 3 trial. The study evaluated neratinib following adjuvant trastuzumab treatment and demonstrated that it significantly improved invasive disease-free survival compared to placebo. The benefit was particularly pronounced in patients who were also hormone receptor-positive, where neratinib was shown to further reduce the risk of recurrence.
Despite its efficacy, the use of neratinib is associated with a high incidence of diarrhea, which can be a limiting factor for some patients. However, prophylactic use of antidiarrheal medications and dose modifications can help manage this side effect. The decision to use neratinib is often based on a careful consideration of the potential benefits and risks, as well as the patient's prior treatments and overall health. Nerlynx continues to be an important option for extending disease-free survival in patients with early-stage HER2-positive breast cancer, particularly in those who have completed trastuzumab-based adjuvant therapy.
Regulatory Agency Approvals
Perjeta
Nerlynx
Access Perjeta or Nerlynx today
If Perjeta or Nerlynx are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us